Cisplatin and Gemcitabine

DRUG3 trials

Sponsors

University of Zurich, Delcath Systems Inc., National University Hospital, Singapore

Conditions

Bile Duct CancerCholangiocellular CarcinomaIntrahepatic CholangiocarcinomaNasopharyngeal Cancer

Phase 1

Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.

CompletedNCT01073839

University of ZurichCholangiocellular Carcinoma

Start: 2008-08-31End: 2015-08-31Updated: 2015-09-18

Phase 2

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Delcath Systems Inc.Bile Duct Cancer, Intrahepatic Cholangiocarcinoma

Start: 2018-04-10End: 2023-05-31Target: 295Updated: 2022-03-24

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

RecruitingNCT05305131

National University Hospital, SingaporeNasopharyngeal Cancer

Start: 2022-03-28End: 2026-12-28Target: 50Updated: 2025-09-23

Related Papers

Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.

2018-01-1128 citations